Innovation in Postpartum Care for Women With Hypertensive Disorders of Pregnancy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03613714|
Recruitment Status : Recruiting
First Posted : August 3, 2018
Last Update Posted : July 9, 2019
|Condition or disease||Intervention/treatment||Phase|
|Hypertension in Pregnancy Hypertension, Pregnancy-Induced Postpartum Preeclampsia Blood Pressure Disorders||Other: At-home Blood Pressure Monitoring||Not Applicable|
Hypertensive disorders of pregnancy (HDP) affect up to 10% of mother-infant dyads and account for 7.4% of cases of maternal mortality in the United States. Prompt recognition and treatment of hypertension remain one of the key features of management of mothers affected by these conditions. Improving recognition and treatment is of particular importance given that maternal mortality rates continue to rise in the United States. Moreover, mothers affected by HDP are at increased risk of long-term morbidity, such as cardiovascular disease, atherosclerosis, and persistent hypertension outside of pregnancy. Therefore, it is critical to recognize hypertension throughout maternity care, including in the postpartum period.
The postpartum period is a time of major challenges for the new mother and considerable physiologic changes that place the new mother at increased risk of adverse events. For a postpartum woman with a diagnosis of a HDP, the risk of complications extends beyond discharge from maternity care: up to 41% of severe morbidity and mortality from HDP occurs after 48 hours postpartum, as postpartum blood pressures tend to peak 3-6 days after birth. For these reasons, the American College of Obstetricians and Gynecologists (ACOG) and the National Partnership for Maternal Safety recommend early postpartum follow-up for women diagnosed with HDP, in the form of blood pressure (BP) evaluation by a health care provider at 7-10 days postpartum. However, barriers to follow-up, including childcare arrangements, transportation access, and recovery from delivery, limit mothers' ability to adhere to this recommended in-office follow-up. Indeed, attendance at postpartum follow-up visits is poor and reflects significant disparities.
A potential alternative to in-office evaluation is at-home blood pressure (BP) monitoring. At-home BP monitoring is a novel, affordable method to empower, educate, and engage postpartum women affected by HDP. This approach is not in widespread use in the US, despite the American Heart Association indicating that home BP monitoring is recommended for all people with high blood pressure. Within the obstetric population, pilot studies have demonstrated the feasibility and acceptability of remote BP monitoring. However, a randomized trial of postpartum at-home BP monitoring compared with office-based follow-up is lacking.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Primary Purpose:||Supportive Care|
|Official Title:||Innovation in Postpartum Care for Women With Hypertensive Disorders of Pregnancy: A Randomized Trial of Home- Versus Office-Based Blood Pressure Monitoring|
|Actual Study Start Date :||September 1, 2018|
|Estimated Primary Completion Date :||August 31, 2019|
|Estimated Study Completion Date :||September 1, 2019|
Active Comparator: Intervention Group
At-home blood pressure monitoring at 2-5 days post-discharge from the hospital using a digital blood pressure cuff. Participants will receive text message reminders to check blood pressure. Contacted by clinic staff to review blood pressure log.
Other: At-home Blood Pressure Monitoring
Participants will use over-the-counter digital monitor to measure blood pressure and pulse rate at home. Automatically averages the last 3 readings taken over 10 minutes.
Other Name: Digital Blood Pressure monitoring cuff
No Intervention: Usual Care
Blood pressure monitoring assessment will be done at 2-5 days post-discharge in the office. Participants will be given high blood pressure information hand-outs and instructed to follow-up in obstetric clinic for blood pressure check within 5 days after discharge from the hospital.
- Percentage of participants who undergo a BP evaluation by clinic staff at 2-5 days post-discharge [ Time Frame: 2-5 Days Post Hospital Discharge ]BP evaluation will be counted if performed by clinic staff via telephone or in person if documented in the medical record.
- Percentage of participants readmitted for inpatient management of severe hypertension within 2 weeks of delivery [ Time Frame: 2 weeks from delivery ]
- Percentage of participants readmitted within 2 weeks of delivery [ Time Frame: 2 weeks of delivery ]Readmission, regardless of indication, within 2 weeks of delivery
- Percentage of participants requiring OB triage evaluation for severe hypertension within 2 weeks of delivery [ Time Frame: 2 weeks after delivery ]
- Percentage of participants with severe hypertension who present to OB triage or Emergency Department for recommended same-day evaluation [ Time Frame: Within 24 hours after BP evaluation ]Includes those diagnosed with severe hypertension in the office or through phone follow-up
- Percentage of attendance to recommended 4-to-6-week postpartum visit [ Time Frame: Up to 6 weeks postpartum ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03613714
|Contact: Angelica Glover, MDemail@example.com|
|Contact: Karen Dorman, RNfirstname.lastname@example.org|
|United States, North Carolina|
|University of North Carolina at Chapel Hill||Recruiting|
|Chapel Hill, North Carolina, United States, 27599|
|Contact: Angelica Glover, MD|
|Principal Investigator:||Angelica Glover, MD||University of North Carolina, Chapel Hill|